186 related articles for article (PubMed ID: 34435932)
21. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
22. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
[TBL] [Abstract][Full Text] [Related]
24. [Burden of Pneumococcal Meningitis and Bacteremia, Serotype Distribution and Antibiotic Resistance in Healthy Children After Conjugated Pneumococcal Vaccine Implementation: Single Center Experience].
Özdemir H; Ekin Dağ N; Çakmak Taşkın E; Konca HK; Arga G; Nar Ötgün S; Güriz H; Elhan A; Çiftçi E; İnce E
Mikrobiyol Bul; 2021 Oct; 55(4):492-506. PubMed ID: 34666651
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
Xiaofei L; Yudan LI; Qinghui C; Jiaming S; Benfeng Z; Youyi Z; Biying W; Lijun Y; Jun Z; Jianmei T; Lin L; Xuejun S; Genming Z; Tao Z
Vaccine; 2024 Feb; 42(6):1275-1282. PubMed ID: 38296700
[TBL] [Abstract][Full Text] [Related]
26. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
[TBL] [Abstract][Full Text] [Related]
27. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
[TBL] [Abstract][Full Text] [Related]
28. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
29. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
[TBL] [Abstract][Full Text] [Related]
31. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
[TBL] [Abstract][Full Text] [Related]
32. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
[TBL] [Abstract][Full Text] [Related]
34. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
Hu T; Weiss T; Owusu-Edusei K; Petigara T
J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
[TBL] [Abstract][Full Text] [Related]
35. 13-valent pneumococcal conjugate vaccine (PCV13).
Jefferies JM; Macdonald E; Faust SN; Clarke SC
Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
[TBL] [Abstract][Full Text] [Related]
36. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
Link-Gelles R; Taylor T; Moore MR;
Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
[TBL] [Abstract][Full Text] [Related]
37. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
38. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
[TBL] [Abstract][Full Text] [Related]
39. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
